Pharmaökonomie
Die compact-Studie
Cost Management in Patients With Type 2 Diabetes:
Pioglitazone (Actos®) Compared To Other Antidiabetic Agents
Die ACTION!-Studie
Actos®
Cost Effects in Patients with Type 2 Diabetes:
Importance of Insulin Resistance
Phazit
Pharmaökonomische Anwendungsbeobachtung
zur supplementären Insulintherapie